



Member-at-Large Candidate



Daniel Bow, Ph.D.
AbbVie Inc.

Daniel (Dan) Bow, Ph.D., is currently a research fellow in the Drug Metabolism, Pharmacokinetic, and Bioanalysis group (DMPK-BA) at AbbVie in North Chicago, Illinois. He leads a team responsible for pre-clinical in vivo pharmacokinetics (PK), and translational modeling (including physiologically based pharmacokinetic modeling) to support human dose and drug-drug interaction predictions. Additionally, he heads up a team of DMPK-BA project representatives supporting discovery and development programs for chemical entities across multiple therapeutic areas.

Bow received his bachelor's degree in biomedical science and a doctorate from the University of Aberdeen, Scotland. His doctorate research focused on renal organic anion and cation transport function. He continued research in the drug transporter field with a visiting fellow position at the National Institute of Environmental Health Sciences and a post-doctoral position at the University of North Carolina at Chapel Hill. He has been with AbbVie for 15 years and over his career held several roles of increasing responsibility within the DMPK-BA organization. He has continued to actively contribute to the advancement of DMPK science through publishing and presenting in the field of drug transporters and translational modeling.

Bow has been a volunteer with several organizations supporting pharmaceutical sciences as well as contributing his time to the academic community through providing lectures or webinar content. He has been a member of the International Transporter Consortium (ITC) and involved with several working groups through the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium). He is currently the co-chair of the IQ Consortium's Transporter working group investigating the in vitro to clinical translation of drug transporter data.

Bow has been an active member of AAPS since 2007 supporting multiple initiatives and helping to drive programming content. He was the chair of the Drug Transporter focus group (2014–2016) and co-chair of the AAPS/ITC workshop in 2013. He was also the chair (2017–2018) of the AAPS Pharmacokinetics, Pharmacodynamics, and Drug Metabolism section and a track chair for the 2018 PharmSci 360 meeting. In 2021 he was appointed as a committee member of the newly formed AAPS Scientific Advisory Committee.

Why are you interested in serving AAPS in the capacity of member-at-large and how has your experience prepared you to lead AAPS?

"If you had asked me in high school to predict what I'd be doing in the year 2022, I don't think I would ever have guessed that I would be working for a global biopharmaceutical company, leading a team of around 20 drug development scientists, all working to get new medicines to patients.

"My scientific career began as a graduate student back in my homeland of Scotland and was followed by postdoctoral positions within government and academia in the U.S. before moving to industry in 2007. It was around that time where I had my first exposure to AAPS as postdoctoral fellow. I was invited to speak in a poster-podium session at the annual meeting and afforded the opportunity to share my research findings with the scientific

community. I believe my introduction to AAPS at that time helped shape my career over the last decade enabling my growth as a both a scientist and leader.

“Following that first meeting, I quickly became a member of AAPS and joined the Transporter Focus Group Steering Committee. Since then, I have been actively involved as a volunteer and have experienced the multiple ways our members receive value from the association. I have been lucky to interact and engage with our members in many ways including through volunteering on several committees, leadership of the former Pharmacokinetics, Pharmacodynamics, and Drug Metabolism section, and as a member of the PharmSci 360 Scientific Programming Committee. AAPS has provided me access to learning about advances in pharmaceutical science and has helped me build a valuable network of trusted peers.

“I would love to continue to give back to AAPS, as member-at-large, acting as an ambassador for the association and helping ensure all our members are afforded the same benefits as me. I would like to help the organization, in an ever-evolving world, stay relevant to our members by providing forums to deliver cutting-edge science and career development support. I believe my contributions to AAPS, along with my extensive industrial leadership experience has helped me understand the challenges that scientists face whether in academia, industry, or regulatory. I believe I can help the association continue to deliver on the vision to create a community with AAPS’ mission to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health.”